350 related articles for article (PubMed ID: 18989934)
1. The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant Enterococci.
Arnusch CJ; Bonvin AM; Verel AM; Jansen WT; Liskamp RM; de Kruijff B; Pieters RJ; Breukink E
Biochemistry; 2008 Dec; 47(48):12661-3. PubMed ID: 18989934
[TBL] [Abstract][Full Text] [Related]
2. Importance of the structure of vancomycin binding pocket in designing compounds active against vancomycin-resistant enterococci (VRE).
Jia Y; Bois-Choussy M; Malabarba A; Brunati C; Zhu J
J Antibiot (Tokyo); 2006 Sep; 59(9):543-52. PubMed ID: 17136887
[TBL] [Abstract][Full Text] [Related]
3. Resistance of Gram-positive bacteria to nisin is not determined by lipid II levels.
Kramer NE; Smid EJ; Kok J; de Kruijff B; Kuipers OP; Breukink E
FEMS Microbiol Lett; 2004 Oct; 239(1):157-61. PubMed ID: 15451114
[TBL] [Abstract][Full Text] [Related]
4. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics.
de Kruijff B; van Dam V; Breukink E
Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):117-21. PubMed ID: 19008088
[TBL] [Abstract][Full Text] [Related]
5. Differential inhibition of Staphylococcus aureus PBP2 by glycopeptide antibiotics.
Leimkuhler C; Chen L; Barrett D; Panzone G; Sun B; Falcone B; Oberthür M; Donadio S; Walker S; Kahne D
J Am Chem Soc; 2005 Mar; 127(10):3250-1. PubMed ID: 15755121
[TBL] [Abstract][Full Text] [Related]
6. Targeting extracellular pyrophosphates underpins the high selectivity of nisin.
Bonev BB; Breukink E; Swiezewska E; De Kruijff B; Watts A
FASEB J; 2004 Dec; 18(15):1862-9. PubMed ID: 15576489
[TBL] [Abstract][Full Text] [Related]
7. Expanding role of lipid II as a target for lantibiotics.
Martin NI; Breukink E
Future Microbiol; 2007 Oct; 2(5):513-25. PubMed ID: 17927474
[TBL] [Abstract][Full Text] [Related]
8. Getting closer to the real bacterial cell wall target: biomolecular interactions of water-soluble lipid II with glycopeptide antibiotics.
Vollmerhaus PJ; Breukink E; Heck AJ
Chemistry; 2003 Apr; 9(7):1556-65. PubMed ID: 12658654
[TBL] [Abstract][Full Text] [Related]
9. Multivalent antibiotics via metal complexes: potent divalent vancomycins against vancomycin-resistant enterococci.
Xing B; Yu CW; Ho PL; Chow KH; Cheung T; Gu H; Cai Z; Xu B
J Med Chem; 2003 Nov; 46(23):4904-9. PubMed ID: 14584941
[TBL] [Abstract][Full Text] [Related]
10. Selective cleavage of D-Ala-D-Lac by small molecules: re-sensitizing resistant bacteria to vancomycin.
Chiosis G; Boneca IG
Science; 2001 Aug; 293(5534):1484-7. PubMed ID: 11520986
[TBL] [Abstract][Full Text] [Related]
11. Reengineering Antibiotics to Combat Bacterial Resistance: Click Chemistry [1,2,3]-Triazole Vancomycin Dimers with Potent Activity against MRSA and VRE.
Silverman SM; Moses JE; Sharpless KB
Chemistry; 2017 Jan; 23(1):79-83. PubMed ID: 27747932
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of calozeyloxanthone isolated from Calophyllum species against vancomycin-resistant Enterococci (VRE) and synergism with antibiotics.
Sakagami Y; Kajimura K; Wijesinghe WM; Dharmaratne HR
Planta Med; 2002 Jun; 68(6):541-3. PubMed ID: 12094300
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of bicyclic alkene-/alkane-bridged nisin mimics by ring-closing metathesis and their biochemical evaluation as lipid II binders: toward the design of potential novel antibiotics.
Ghalit N; Reichwein JF; Hilbers HW; Breukink E; Rijkers DT; Liskamp RM
Chembiochem; 2007 Sep; 8(13):1540-54. PubMed ID: 17674393
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria.
Nakama Y; Yoshida O; Yoda M; Araki K; Sawada Y; Nakamura J; Xu S; Miura K; Maki H; Arimoto H
J Med Chem; 2010 Mar; 53(6):2528-33. PubMed ID: 20180534
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial activity of phytochemicals isolated from Erythrina zeyheri against vancomycin-resistant enterococci and their combinations with vancomycin.
Sato M; Tanaka H; Oh-Uchi T; Fukai T; Etoh H; Yamaguchi R
Phytother Res; 2004 Nov; 18(11):906-10. PubMed ID: 15597305
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activities of disinfectants against vancomycin-resistant enterococci.
Sakagami Y; Kajimura K
J Hosp Infect; 2002 Feb; 50(2):140-4. PubMed ID: 11846542
[TBL] [Abstract][Full Text] [Related]
17. Lipid II as a target for antibiotics.
Breukink E; de Kruijff B
Nat Rev Drug Discov; 2006 Apr; 5(4):321-32. PubMed ID: 16531990
[TBL] [Abstract][Full Text] [Related]
18. Structure determination and total synthesis of bottromycin A2: a potent antibiotic against MRSA and VRE.
Shimamura H; Gouda H; Nagai K; Hirose T; Ichioka M; Furuya Y; Kobayashi Y; Hirono S; Sunazuka T; Omura S
Angew Chem Int Ed Engl; 2009; 48(5):914-7. PubMed ID: 19115340
[No Abstract] [Full Text] [Related]
19. Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors.
Müller A; Ulm H; Reder-Christ K; Sahl HG; Schneider T
Microb Drug Resist; 2012 Jun; 18(3):261-70. PubMed ID: 22432708
[TBL] [Abstract][Full Text] [Related]
20. Semisynthetic Lipopeptides Derived from Nisin Display Antibacterial Activity and Lipid II Binding on Par with That of the Parent Compound.
Koopmans T; Wood TM; 't Hart P; Kleijn LH; Hendrickx AP; Willems RJ; Breukink E; Martin NI
J Am Chem Soc; 2015 Jul; 137(29):9382-9. PubMed ID: 26122963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
